Published: 1 December 2022

Publications

Recent approvals: new active ingredients or new indications

Prescriber Update 43(4): 58
December 2022
 

For the period 16 July to 15 October 2022.

Recent approvals of medicines with new active ingredients

Trade name (active ingredient) Dose form: strength(s) Therapeutic area
Cresemba (isavuconazonium) Powder for injection: 200mg
Capsule: 100mg
Antifungal agent for treatment of invasive aspergillosis, mucormycosis
Spy Agent Green (indocyanine green) Powder for injection: 25mg Fluorescence imaging agent
Entyvio (vedolizumab) Powder for injection: 300mg Ulcerative colitis, Crohn’s disease
Nubeqa (darolutamide) Tablet: 300mg Non-metastatic castration resistant prostate cancer
Evusheld (cilgavimab + tixagevimab)* Solution for injection: 100mg/mL Pre-exposure prophylaxis of COVID-19
* Provisional approval

Approved medicines with new indications

There were no approved medicines with new indications for the period 16 July 2022 to 15 October 2022.

See the Medsafe website for:
Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /